RU2004135563A - Лекарственное средство для лечения повышенной активности мочевого пузыря - Google Patents
Лекарственное средство для лечения повышенной активности мочевого пузыря Download PDFInfo
- Publication number
- RU2004135563A RU2004135563A RU2004135563/15A RU2004135563A RU2004135563A RU 2004135563 A RU2004135563 A RU 2004135563A RU 2004135563/15 A RU2004135563/15 A RU 2004135563/15A RU 2004135563 A RU2004135563 A RU 2004135563A RU 2004135563 A RU2004135563 A RU 2004135563A
- Authority
- RU
- Russia
- Prior art keywords
- treating
- bladder
- activity
- increased
- tamsulosin
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims 9
- 150000003839 salts Chemical class 0.000 claims 6
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims 5
- 229960002613 tamsulosin Drugs 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 3
- 239000003149 muscarinic antagonist Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 claims 1
- 229960003198 tamsulosin hydrochloride Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (8)
1. Фармацевтическая композиция для лечения повышенной активности мочевого пузыря, где указанная композиция содержит в качестве активного ингредиента тамсулозин или его фармацевтически приемлемую соль.
2. Фармацевтическая композиция для лечения повышенной активности мочевого пузыря по п.1, в котором указанная композиция содержит гидрохлорид тамсулозина.
3. Фармацевтическая композиция для лечения повышенной активности мочевого пузыря по п.1 или 2, в котором указанная композиция содержит антагонист мускариновых рецепторов.
4. Фармацевтическая композиция для лечения повышенной активности мочевого пузыря по п.3, в котором указанная композиция содержит в качестве активного ингредиента хинуклидин-3’-ил-1-фенил-1,2,3,4-тетрагидроизохинолин-2-карбоксилат или его соль.
5. Применение тамсулозина или его фармацевтически приемлемой соли для производства лекарственного средства против повышенной активности мочевого пузыря.
6. Применение тамсулозина или его фармацевтически приемлемой соли для производства лекарственного средства, используемого в сочетании с антагонистом мускариновых рецепторов при лечении повышенной активности мочевого пузыря.
7. Способ лечения повышенной активности мочевого пузыря, где указанный способ предусматривает введение терапевтически эффективного количества тамсулозина или его фармацевтически приемлемой соли пациенту.
8. Способ лечения повышенной активности мочевого пузыря, где указанный способ предусматривает введение терапевтически эффективного количества тамсулозина или его фармацевтически приемлемой соли пациенту в сочетании с терапевтически эффективным количеством антагонистом мускариновых рецепторов.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002-166408 | 2002-06-07 | ||
| JP2002166408 | 2002-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004135563A true RU2004135563A (ru) | 2005-06-10 |
Family
ID=29727628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004135563/15A RU2004135563A (ru) | 2002-06-07 | 2003-06-05 | Лекарственное средство для лечения повышенной активности мочевого пузыря |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20060035923A1 (ru) |
| EP (1) | EP1552825A4 (ru) |
| JP (1) | JP4466370B2 (ru) |
| KR (1) | KR20050008795A (ru) |
| CN (1) | CN100355419C (ru) |
| AR (1) | AR040248A1 (ru) |
| AU (1) | AU2003242166A1 (ru) |
| BR (1) | BR0311414A (ru) |
| CA (1) | CA2487899A1 (ru) |
| IL (1) | IL165370A0 (ru) |
| MX (1) | MXPA04012070A (ru) |
| NO (1) | NO20050060L (ru) |
| PL (1) | PL372560A1 (ru) |
| RU (1) | RU2004135563A (ru) |
| TW (1) | TW200408387A (ru) |
| WO (1) | WO2003103659A1 (ru) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442387B2 (en) * | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
| US20050175689A1 (en) * | 2003-10-27 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | Coated fine particles containing drug for intrabuccally fast disintegrating tablet |
| US8197846B2 (en) * | 2003-11-10 | 2012-06-12 | Astellas Pharma Inc. | Sustained release pharmaceutical composition |
| CZ23088U1 (cs) * | 2004-03-25 | 2011-12-19 | Astellas Pharma Inc. | Kompozice pevného farmaceutického prípravku solifenacinu nebo jeho soli |
| CN1934109B (zh) * | 2004-03-25 | 2010-06-23 | 安斯泰来制药株式会社 | 用于固体制剂的索非那新或其盐的组合物 |
| SK6196Y1 (sk) * | 2004-12-27 | 2012-08-06 | Astellas Pharma Inc | Stable particulate pharmaceutical composition of solifenacin or its salt, mixture for its preparation and tablet comprising same |
| EP1832288B1 (en) * | 2004-12-27 | 2012-06-20 | Astellas Pharma Inc. | Stable granular pharmaceutical composition of solifenacin or its salt |
| WO2006090759A1 (ja) * | 2005-02-25 | 2006-08-31 | Astellas Pharma Inc. | ソリフェナシン含有医薬 |
| US7815939B2 (en) | 2005-07-20 | 2010-10-19 | Astellas Pharma Inc. | Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms |
| JPWO2009013846A1 (ja) * | 2007-07-20 | 2010-10-07 | アステラス製薬株式会社 | 前立腺肥大に伴う下部尿路症状の改善用医薬組成物 |
| DK2216021T3 (da) * | 2007-11-02 | 2012-11-05 | Astellas Pharma Inc | Farmaceutisk sammensætning til behandling af overaktiv blære |
| CA2709727A1 (en) * | 2007-12-21 | 2009-07-02 | Astellas Pharma Inc. | Pharmaceutical composition for improving lower urinary tract symptoms |
| EP2181707A1 (en) * | 2008-11-04 | 2010-05-05 | Astellas Ireland Co., Ltd. | Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent |
| MY160652A (en) * | 2009-02-04 | 2017-03-15 | Astellas Pharma Inc | Pharmaceutical composition for oral administration |
| US9119878B2 (en) | 2010-07-08 | 2015-09-01 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| KR102027912B1 (ko) * | 2011-02-15 | 2019-10-02 | 지엘팜텍주식회사 | 경구투여용 탐술로신 또는 이의 약제학적으로 허용되는 염을 포함하는 서방성 삼중정제 |
| RU2669565C2 (ru) * | 2012-03-19 | 2018-10-12 | УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения |
| CN102743757A (zh) * | 2012-07-09 | 2012-10-24 | 张家华 | 治疗膀胱流出道梗阻所致膀胱活动过度的药物 |
| US10596127B2 (en) | 2013-03-14 | 2020-03-24 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| CN106265667B (zh) * | 2015-05-18 | 2019-01-25 | 中国科学院生物物理研究所 | 一种氯喹的用途 |
| CN106562968B (zh) * | 2015-10-13 | 2019-08-13 | 南京华威医药科技集团有限公司 | 包含盐酸坦洛辛和琥珀酸索利那新的药物组合物 |
| KR101879133B1 (ko) * | 2017-07-11 | 2018-07-17 | (주)동구바이오제약 | 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법 |
| AU2021265311A1 (en) * | 2020-04-27 | 2022-12-08 | Zim Laboratories Limited | Novel multiparticulate pharmaceutical composition of tamsulosin and solifenacin |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391825A (en) * | 1980-02-08 | 1995-02-21 | Yamanouchi Pharmaceutical Co., Ltd. | Sulfamoyl substituted phenethylamine intermediates |
| NO2005012I1 (no) * | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| US6319920B1 (en) * | 1998-02-27 | 2001-11-20 | Syntex (U.S.A.) Llc | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives |
| TW536402B (en) * | 1998-06-26 | 2003-06-11 | Yamanouchi Pharma Co Ltd | Pharmaceutical composition for the therapy of voiding dysfunction |
| CA2370501C (en) * | 1999-08-09 | 2008-09-16 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical composition for the therapy of lower urinary tract symptoms |
| IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
| DE602004007225T2 (de) * | 2003-04-04 | 2008-03-06 | Dynogen Pharmaceuticals Inc., Waltham | Methode zur behandlung von erkrankungen der unteren harnwege |
-
2003
- 2003-06-05 US US10/517,137 patent/US20060035923A1/en not_active Abandoned
- 2003-06-05 RU RU2004135563/15A patent/RU2004135563A/ru not_active Application Discontinuation
- 2003-06-05 MX MXPA04012070A patent/MXPA04012070A/es active IP Right Grant
- 2003-06-05 PL PL03372560A patent/PL372560A1/xx unknown
- 2003-06-05 JP JP2004510778A patent/JP4466370B2/ja not_active Expired - Lifetime
- 2003-06-05 WO PCT/JP2003/007149 patent/WO2003103659A1/ja not_active Ceased
- 2003-06-05 KR KR10-2004-7019807A patent/KR20050008795A/ko not_active Ceased
- 2003-06-05 CA CA002487899A patent/CA2487899A1/en not_active Abandoned
- 2003-06-05 AU AU2003242166A patent/AU2003242166A1/en not_active Abandoned
- 2003-06-05 BR BR0311414-7A patent/BR0311414A/pt not_active IP Right Cessation
- 2003-06-05 IL IL16537003A patent/IL165370A0/xx unknown
- 2003-06-05 CN CNB038131498A patent/CN100355419C/zh not_active Expired - Fee Related
- 2003-06-05 EP EP03730850A patent/EP1552825A4/en not_active Withdrawn
- 2003-06-06 AR ARP030102019A patent/AR040248A1/es not_active Application Discontinuation
- 2003-06-06 TW TW092115435A patent/TW200408387A/zh unknown
-
2005
- 2005-01-06 NO NO20050060A patent/NO20050060L/no not_active Application Discontinuation
-
2006
- 2006-12-22 US US11/643,762 patent/US20070270459A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4466370B2 (ja) | 2010-05-26 |
| IL165370A0 (en) | 2006-01-15 |
| BR0311414A (pt) | 2005-03-15 |
| CN1658859A (zh) | 2005-08-24 |
| JPWO2003103659A1 (ja) | 2005-10-06 |
| US20060035923A1 (en) | 2006-02-16 |
| KR20050008795A (ko) | 2005-01-21 |
| CN100355419C (zh) | 2007-12-19 |
| TW200408387A (en) | 2004-06-01 |
| PL372560A1 (en) | 2005-07-25 |
| MXPA04012070A (es) | 2005-03-07 |
| AR040248A1 (es) | 2005-03-23 |
| NO20050060L (no) | 2005-03-04 |
| AU2003242166A1 (en) | 2003-12-22 |
| WO2003103659A1 (ja) | 2003-12-18 |
| EP1552825A1 (en) | 2005-07-13 |
| CA2487899A1 (en) | 2003-12-18 |
| US20070270459A1 (en) | 2007-11-22 |
| EP1552825A4 (en) | 2009-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| JP2006501240A5 (ru) | ||
| RU2008116931A (ru) | Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей | |
| GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
| HK19395A (en) | Film-coated solid dosage form of anti-migraine drug | |
| WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| HRP20120798T1 (hr) | Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva | |
| RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| EA200600817A1 (ru) | Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты) | |
| JP2005508963A5 (ru) | ||
| JP2004537500A5 (ru) | ||
| WO2004037207A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | |
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| RU2002122084A (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств | |
| RU2005135649A (ru) | Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги | |
| CA2519789A1 (en) | Aplidine for multiple myeloma treatment | |
| CA2450915A1 (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
| CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| RU2003130641A (ru) | Каппа-опиатные агонисты для лечения заболеваний мочевого пузыря | |
| WO2000076500A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| CA2457982A1 (en) | Use of nefiracetam for treating neurodegeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20070508 |